Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?

Novo Nordisk stock surged on Wednesday after a major policy win, which is seen as a turning point for the drugmaker.

England’s cost-effectiveness watchdog has backed broader use of Wegovy to cut the risk of heart attacks and strokes in overweight or obese adults.

This could eventually open access to about 1.2 million people through the NHS.

For investors, the more interesting question is whether it changes the stock story in a meaningful way.

The development is a useful validation of Wegovy’s medical value rather than a clean reset for Novo’s bruised equity narrative.

NHS backing widens Wegovy’s case

The NICE decision matters because it stretches Wegovy’s investment case beyond obesity treatment.

The company can now think of extending the drug deeper into cardiovascular prevention, an area with far broader strategic implications for a chronic-disease franchise.

The recommendation is based on a study of more than 17,600 participants showing semaglutide cut major heart events by 20% versus placebo.

NICE’s project page also shows that the guidance is still in draft form, with a final draft consultation running from March 25 to April 17, 2026, and expected publication on May 7.

Still, the direction of travel is hard to miss.

NHS England said the treatment could be available within months and described around 1.2 million people with cardiovascular disease as potentially eligible.

If that rollout holds, Novo can argue that Wegovy is no longer just a premium weight-loss product but part of a wider cardiovascular-metabolic platform.

Pricing remains the real stock problem

The difficulty for Novo is that a reimbursement and access win does not erase the pressure building elsewhere in the business.

In February, the company warned that 2026 sales and adjusted operating profit could each fall 5% to 13%.

Chief executive Mike Doustdar described the environment as one of “unprecedented pricing pressure,” with the company facing tougher rebate demands and intensifying competition, especially from Eli Lilly.

Novo cut Ozempic and Wegovy prices again in India after semaglutide’s patent expiry, with some local generic rivals priced as much as 70% lower.

It also launched discounted Wegovy subscription plans in the United States for self-pay patients, offering prices as low as $249 a month.

What analysts say

Wall Street’s recent tone helps explain why a single policy win is unlikely to flip sentiment.

After Novo’s disappointing February CagriSema trial result, J.P. Morgan called it a result that confirmed Lilly’s lead and made it difficult for Novo to win back share.

BMO Capital Markets’ Evan David Seigerman said the company needed more than just the Wegovy pill to “right this ship.”

Jefferies analyst Michael Leuchten said investor attention would likely turn to management’s M&A strategy.

There have been brighter spots.

Novo’s oral Wegovy launch made an encouraging start in the US, with early prescription data pointing to solid uptake.

But even there, analysts cautioned that more data was needed and that price reductions and changing insurance dynamics could still weigh on sales.